 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
160 News |  |
| «123» |
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive (clinicaltrials.gov) - Apr 23, 2018
P1, N=28, Not yet recruiting, Sponsor: Eli Lilly and Company
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Study of LY3314814 in Participants With Liver Impairment (clinicaltrials.gov) - Apr 17, 2018
P1, N=48, Not yet recruiting, Sponsor: Eli Lilly and Company
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion, Trial completion date, Trial primary completion date: A Study of LY3314814 in Healthy Participants (clinicaltrials.gov) - Mar 6, 2018
P1, N=8, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial completion date: Feb 2018 --> Feb 2018 | Trial primary completion date: Feb 2018 --> Feb 2018
- |||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion date, Trial primary completion date: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (clinicaltrials.gov) - Feb 19, 2018
P3, N=1400, Enrolling by invitation, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial completion date: Feb 2018 --> Feb 2018 | Trial primary completion date: Feb 2018 --> Feb 2018 Trial primary completion date: Sep 2020 --> Sep 2021 | Trial completion date: Sep 2020 --> Sep 2021
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Study of LY3314814 in Healthy Participants (clinicaltrials.gov) - Jan 19, 2018
P1, N=8, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2020 --> Sep 2021 | Trial completion date: Sep 2020 --> Sep 2021 Not yet recruiting --> Recruiting
- ||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Enrollment closed: AMARANTH: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (clinicaltrials.gov) - Oct 20, 2017
P2/3, N=2202, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial primary completion date: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (clinicaltrials.gov) - Aug 28, 2017
P3, N=1400, Enrolling by invitation, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2020 --> Sep 2020
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Study of LY3314814 in Healthy Participants (clinicaltrials.gov) - Jul 19, 2017
P1, N=8, Not yet recruiting, Sponsor: Eli Lilly and Company
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (clinicaltrials.gov) - Jun 20, 2017
P1, N=42, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Jan 2020 --> Sep 2020 Active, not recruiting --> Completed
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment closed: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (clinicaltrials.gov) - May 3, 2017
P1, N=42, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment status: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (clinicaltrials.gov) - May 2, 2017
P3, N=1400, Enrolling by invitation, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment change: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (clinicaltrials.gov) - Mar 24, 2017
P1, N=42, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Enrolling by invitation N=28 --> 42
- |||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (clinicaltrials.gov) - Mar 22, 2017
P3, N=1400, Recruiting, Sponsor: Eli Lilly and Company
N=28 --> 42 Not yet recruiting --> Recruiting
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (clinicaltrials.gov) - Feb 10, 2017
P1, N=28, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (clinicaltrials.gov) - Jan 12, 2017
P1, N=28, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||||||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P3 trial: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (clinicaltrials.gov) - Nov 22, 2016
P3, N=1400, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: DAYBREAK-ALZ: A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (clinicaltrials.gov) - Jun 29, 2016
P3, N=1899, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P3 trial: DAYBREAK-ALZ: A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (clinicaltrials.gov) - May 26, 2016
P3, N=1899, Not yet recruiting, Sponsor: Eli Lilly and Company
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: A Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Apr 6, 2016
P1, N=18, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Jan 26, 2016
P1, N=60, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Jan 26, 2016
P1, N=18, Not yet recruiting, Sponsor: Eli Lilly and Company
- || lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment closed: A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Dec 24, 2015
P1, N=60, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants (clinicaltrials.gov) - Dec 18, 2015
P1, N=17, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment closed: A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants (clinicaltrials.gov) - Nov 17, 2015
P1, N=17, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Oct 5, 2015
P1, N=60, Not yet recruiting, Sponsor: Eli Lilly and Company
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants (clinicaltrials.gov) - Oct 3, 2015
P1, N=17, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants (clinicaltrials.gov) - Sep 4, 2015
P1, N=17, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Aug 17, 2015
P1, N=82, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Trial primary completion date: AMARANTH: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (clinicaltrials.gov) - Jun 22, 2015
P2/3, N=2202, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Trial primary completion date: May 2019 --> Oct 2019
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment open: A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Apr 28, 2015
P1, N=82, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: May 2019 --> Oct 2019 Not yet recruiting --> Recruiting
- ||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Enrollment change: AMARANTH: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (clinicaltrials.gov) - Apr 14, 2015
P2/3, N=2202, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=1551 --> 2202
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (clinicaltrials.gov) - Apr 2, 2015
P1, N=82, Not yet recruiting, Sponsor: AstraZeneca
- |||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Enrollment open: AMARANTH: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (clinicaltrials.gov) - Oct 17, 2014
P2/3, N=1551, Recruiting, Sponsor: AstraZeneca
N=1551 --> 2202 Not yet recruiting --> Recruiting
- |||||||||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, New P2/3 trial: AMARANTH: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (clinicaltrials.gov) - Sep 22, 2014
P2/3, N=1551, Not yet recruiting, Sponsor: AstraZeneca
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Trial completion, Enrollment change: A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers (clinicaltrials.gov) - Sep 22, 2014
P1, N=114, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed | N=40 --> 114
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: AZD3293TQT: AZD3293 Thorough QT Study in Healthy Male Volunteers (clinicaltrials.gov) - Jul 4, 2014
P1, N=52, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | N=40 --> 114 Active, not recruiting --> Completed
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment change: AZD3293hADME: A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (clinicaltrials.gov) - Jun 17, 2014
P1, N=12, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=16 --> 12
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion, Enrollment change: AZD3293hADME: A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (clinicaltrials.gov) - Jun 17, 2014
P1, N=12, Completed, Sponsor: AstraZeneca
N=16 --> 12 Active, not recruiting --> Completed | N=16 --> 12
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment closed: AZD3293hADME: A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (clinicaltrials.gov) - May 9, 2014
P1, N=16, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=16 --> 12 Not yet recruiting --> Active, not recruiting
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: AZD3293hADME: A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (clinicaltrials.gov) - Apr 28, 2014
P1, N=16, Not yet recruiting, Sponsor: AstraZeneca
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment change: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (clinicaltrials.gov) - Apr 22, 2014
P1, N=1, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Active, not recruiting N=16 --> 1
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (clinicaltrials.gov) - Apr 22, 2014
P1, N=1, Completed, Sponsor: AstraZeneca
N=16 --> 1 Recruiting --> Completed
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Trial completion: AZD3293DDI: A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate (clinicaltrials.gov) - Apr 22, 2014
P1, N=56, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Completed
- || lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Enrollment closed: AZD3293TQT: AZD3293 Thorough QT Study in Healthy Male Volunteers (clinicaltrials.gov) - Apr 7, 2014
P1, N=52, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Active, not recruiting
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Trial completion: A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients (clinicaltrials.gov) - Apr 1, 2014
P1, N=47, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: AZD3293TQT: AZD3293 Thorough QT Study in Healthy Male Volunteers (clinicaltrials.gov) - Jan 16, 2014
P1, N=52, Active, not recruiting, Sponsor: AstraZeneca
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (clinicaltrials.gov) - Jan 15, 2014
P1, N=1, Completed, Sponsor: AstraZeneca
- lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Enrollment open: A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers (clinicaltrials.gov) - Jan 14, 2014
P1, N=40, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: AZD3293DDI: A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate (clinicaltrials.gov) - Dec 11, 2013
P1, N=56, Completed, Sponsor: AstraZeneca